City Therapeutics priced its Nasdaq IPO at $18 per share, raising close to $200 million to advance its clinical-stage RNA interference (RNAi) pipeline. The offering, led by Goldman Sachs, Jefferies, Stifel and Oppenheimer, values the biotech founded in 2023 at roughly $931 million.
🔑 Key takeaways
- IPO priced at $18.00 per share, the midpoint of the marketed range
- 11,111,111 ordinary shares issued, generating $199.98M in gross proceeds
- Implied market capitalization at the IPO price: $931M
- Shares began trading on the Nasdaq Global Market on October 16, 2026 under the ticker “CTY”
- Three RNAi programs in the clinic, including lead candidate CITY-FXI in Phase 1
An upsized offering priced at the midpoint
The RNAi biotech saw its offering size lifted to 11,111,111 ordinary shares, up from the 9.72 million initially filed in the prospectus. The $18.00 price landed exactly at the midpoint of a tightened indicative range. Gross proceeds therefore reached $199.98 million before underwriting discounts, commissions and other offering expenses.
At the IPO price, City Therapeutics carried an implied market capitalization of $931 million. The company also granted underwriters a 30-day greenshoe option to purchase up to 1,666,666 additional shares at the IPO price, net of discounts and commissions. All shares in the offering are newly created, with no secondary sales by founders or existing backers.
Listing timeline and bookrunners
Filings with the Securities and Exchange Commission (SEC) were declared effective on October 15, 2026. Shares then began trading on the Nasdaq Global Market under the ticker “CTY” on October 16, 2026, with the offering expected to close on October 19, 2026 subject to customary closing conditions. Four banks served as co-lead managers: Goldman Sachs & Co. LLC, Jefferies, Stifel and Oppenheimer & Co.
Strong pipeline, but profitability still distant
Founded in July 2023, City Therapeutics describes itself as a company “led by pioneers and experts in the RNAi field.” It claims three programs moved toward or into the clinic in less than three years, with a stated goal of filing one to two investigational new drug (IND) applications per year through its City Platform.
Financially, the company remains deeply unprofitable, posting a net loss of $87.67 million against just $14.34 million in collaboration revenue over the twelve months ended June 30, 2026, according to prospectus data cited by IPOScoop. The revenue mix therefore stays tightly concentrated on a handful of industrial partners rather than product sales.
“We have made rapid progress since our founding in 2023, with three clinical programs in less than three years.”
City Therapeutics, IPO prospectus
Three RNAi programs targeting high-need indications
City Therapeutics’ portfolio is built around three lead candidates positioned in indications where therapeutic options remain limited or non-existent.
| Program | Target / mechanism | Indication | Stage |
|---|---|---|---|
| CITY-FXI | siRNA against FXI | Prevention of thromboembolic events (stroke, AF) | Phase 1, data late 2026; Phase 2 (TKA) mid-2027 |
| CITY-RBP4 | GalNAc-conjugated siRNA against RBP4 | Stargardt disease | Preclinical / IND-enabling |
| CITY-TFR2 | GalNAc-conjugated siRNA against TFR2 | Anemia of chronic disease | Preclinical / IND-enabling |
CITY-FXI is the most advanced candidate. It targets Factor XI to lower thromboembolic risk while mitigating bleeding risk, a trade-off current anticoagulants (heparins, DOACs, warfarin) struggle to deliver. Additional Phase 1 data are expected late 2026, with a Phase 2 study in total knee arthroplasty (TKA) scheduled for mid-2027. CITY-RBP4 is being developed for Stargardt disease, described as the most common inherited macular degeneration in children and young adults, with no approved treatment to date. CITY-TFR2 addresses anemia of chronic disease, which the prospectus says accounts for up to 40% of all anemias and affects more than five million people in the United States.
Big-pharma validation through Bausch + Lomb and Biogen
City Therapeutics has signed collaboration and license agreements with Bausch + Lomb and Biogen, two heavyweights in ophthalmology and neurology. These partnerships deliver both collaboration revenue ($14.34M in the fiscal year ended June 2026) and external validation of the City Platform technology, even if the company remains a long way from profitability. For investors, the caliber of the industrial counterparties is a reassuring signal on the underlying science, though it does not offset the early-stage nature of the portfolio.
Conclusion: a textbook clinical-stage biotech IPO
City Therapeutics’ market debut embodies the classic profile of a clinical-stage RNAi biotech: roughly $1 billion market capitalization, sizeable net losses, a valuation pegged to an early-stage pipeline and marquee industrial partnerships. For investors, near-term catalysts include additional Phase 1 data for CITY-FXI expected late 2026, followed by the launch of a Phase 2 study in total knee arthroplasty scheduled for mid-2027. A full exercise of the 1.66-million-share greenshoe would add about $30M of incremental gross proceeds, potentially funding the next IND filings for CITY-RBP4 and CITY-TFR2.
Over the longer term, progress of CITY-RBP4 (Stargardt) and CITY-TFR2 (chronic anemia), together with potential new IND filings via the City Platform, will determine whether the $931M IPO-day valuation becomes a durable equity story, or whether the typical post-debut pressure on unprofitable biotechs reasserts itself after the first-session euphoria fades.
Sources
This article is published for informational and educational purposes only. It does not constitute investment advice. Do your own research (DYOR) before making any decision.
